CervoMed director granted 8,150 stock options

CervoMed Inc. director and 10% owner Joshua S. Boger received a stock option grant in connection with his election to the board.

Rhea-AI Filing Summary

CervoMed Inc. director and 10% owner Joshua S. Boger received a stock option grant in connection with his election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share, expiring on June 8, 2036. These shares vest in substantially equal monthly installments over one year starting on June 30, 2026, conditioned on his continued board service.

Insider Trade Summary

Grant/Award: 8,150 shares

Grant/Award 1 txn

Insider BOGER JOSHUA S

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,150	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 8,150 contracts (Direct)

Footnotes (1)

1. F1. On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option grant size: 8,150 shares Exercise price: $2.91 per share Expiration date: June 8, 2036 +1 more

4 metrics

Option grant size 8,150 shares Stock Option (Right to Buy) granted June 8, 2026

Exercise price $2.91 per share Exercise price of granted stock options

Expiration date June 8, 2036 Option grant expiration

Underlying shares 8,150 shares Common stock underlying the options

Key Terms

Stock Option (Right to Buy), 2025 Equity Incentive Plan, non-employee director compensation policy, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2025 Equity Incentive Plan financial

"common stock under the Issuer's 2025 Equity Incentive Plan"

non-employee director compensation policy financial

"in accordance with the terms of the Issuer's non-employee director compensation policy"

vesting financial

"shares of common stock underlying the award will vest on a monthly basis"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CervoMed (CRVO) director Joshua S. Boger receive in this Form 4?

He received a stock option grant for 8,150 shares of CervoMed common stock. The options were awarded in connection with his election to the board under the 2025 Equity Incentive Plan.

What is the exercise price of the options granted to Joshua S. Boger at CervoMed (CRVO)?

The options have an exercise price of $2.91 per share. This is the price at which he can buy CervoMed common stock once the options vest and become exercisable.

How do the CervoMed (CRVO) options granted to Joshua S. Boger vest?

The 8,150-share option grant vests monthly over one year. Vesting occurs in substantially equal 1/12th increments on the last day of each month beginning June 30, 2026, subject to continued board service.

When do the stock options granted to CervoMed (CRVO) director Joshua S. Boger expire?

The options expire on June 8, 2036. If unexercised by that date, the right to purchase CervoMed common stock at $2.91 per share will lapse under the grant terms.

Why did CervoMed (CRVO) grant these options to Joshua S. Boger?

The options were granted in connection with his election to CervoMed’s board at the 2026 Annual Meeting. The award was made under the company’s 2025 Equity Incentive Plan and non-employee director compensation policy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 07:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOGER JOSHUA S

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.91	06/08/2026		A		8,150		(1)	06/08/2036	Common Stock	8,150	$0	8,150	D

Explanation of Responses:

1. On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)